自噬
生物
葡萄膜炎
细胞生物学
条件基因敲除
免疫学
生物发生
炎症
自身免疫性疾病
外周血单个核细胞
自噬体
RAR相关孤儿受体γ
癌症研究
过继性细胞移植
信号转导
自身免疫
刺激
CD44细胞
白细胞介素17
焊剂(冶金)
ATG16L1
乙酰化
下调和上调
平衡
基因剔除小鼠
未折叠蛋白反应
精氨酸酶
巨噬细胞极化
转录组
疾病
作者
Yingjun Cai,Lihui Xie,Bowen Li,Bolin Chen,Jing Zou,Huizhuo Xu
出处
期刊:Autophagy
[Taylor & Francis]
日期:2026-07-15
卷期号:: 1-20
被引量:1
标识
DOI:10.1080/15548627.2026.2704443
摘要
Autoimmune uveitis is a vision-threatening inflammatory disorder driven by dysregulated T helper 17 (Th17) responses, yet therapeutic strategies targeting Th17 differentiation are lacking. Through transcriptomic screening of an experimental autoimmune uveitis (EAU) model and validation in peripheral blood mononuclear cells from Vogt-Koyanagi-Harada patients, we identified MAP1S (microtubule-associated protein 1S) as a pivotal, conserved regulator. Here, we demonstrate that MAP1S constrains pathogenic Th17 responses and alleviates EAU through a dual mechanism coordinating transcriptional control and autophagic degradation. Mechanistically, MAP1S binds to EGR2 (early growth response 2) and restrains its acetylation at Lys368, thereby suppressing Lcn2 (lipocalin 2) transcription. Besides, MAP1S facilitates autophagosome biogenesis and lysosomal trafficking, promoting the autophagic clearance of LCN2 protein. Notably, MAP1S deficiency enhances EGR2 acetylation, increases Lcn2 transcription, disrupts autophagosome trafficking, impairs LCN2 degradation, and promotes LCN2 accumulation, collectively driving Th17 polarization and exacerbating EAU pathology. Adoptive transfer of cervical lymph node cells from map1s knockout mice reproduced severe disease in wild-type recipients. Moreover, pharmacological activation of MAP1S with spermidine suppressed Th17 responses and alleviated disease severity. Our findings establish MAP1S as a critical node integrating acetylation signaling of EGR2 and autophagic flux to govern LCN2 homeostasis and Th17 pathogenicity, revealing a promising therapeutic target for autoimmune uveitis and potentially other Th17-mediated diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI